Recommended Articles
Fundraising

Estuary Biotherapeutics Raises $93M Series A to Develop Gene Therapies for Polycystic Kidney Disease

By Angeled · October 18, 2026 · Fundraising
Estuary Biotherapeutics Raises $93M Series A to Develop Gene Therapies for Polycystic Kidney Disease
Estuary Biotherapeutics Raises $93M Series A to Develop Gene Therapies for Polycystic Kidney Disease

Estuary Biotherapeutics, a newly launched biotech, has raised a $93 million Series A to push two gene therapies for autosomal dominant polycystic kidney disease (ADPKD) into clinical trials. The round was announced on October 16, 2026, and gives the company $103 million on hand when combined with $10 million in previously raised seed funding.

The round and the investors

The Series A was led by a syndicate of blue-chip life sciences investors:

  • RA Capital Management and Deep Track Capital
  • Biogen New Ventures, UPMC Enterprises, and Pivotal bioVenture Partners
  • The National Kidney Foundation Innovation Fund
  • A family office connected to an individual living with ADPKD
  • 4BIO Capital and GV

The presence of the National Kidney Foundation's venture arm and a family office with a personal connection to the disease signals an unusually patient-aligned capital structure — a pattern that has become more common in rare-disease and chronic-disease biotech, where advocacy-linked funds participate directly in early rounds.

What is ADPKD?

Autosomal dominant polycystic kidney disease is one of the most common inherited genetic disorders. It affects roughly 1 in every 500–1,000 people — about 600,000 in the United States and an estimated 12 million worldwide. Mutations in the PKD1 or PKD2 genes cause fluid-filled cysts to grow progressively in the kidneys, enlarging the organs and destroying normal tissue. Over decades, most patients progress to end-stage renal disease requiring dialysis or a kidney transplant.

Treatment options are strikingly thin for a disease this common. The only FDA-approved drug that slows progression is tolvaptan (marketed as Jynarque), approved in 2018 — a medication with meaningful tolerability issues and limited eligible population. There is no approved gene therapy for any kidney disease, which makes Estuary's target both high-unmet-need and technically ambitious.

Why this raise matters

The size of the round is the headline. Series A financings above $90 million in biotech are now typically reserved for companies with multiple clinical-stage assets or platform deals; a stealth-stage company commanding $93 million to fund two preclinical gene therapies reflects two things:

  1. Investor confidence in the kidney as a gene-therapy target. The kidney has historically resisted gene therapy because delivering vectors to the right cells — without off-target effects — is technically difficult. If Estuary's approach works, it opens a large organ market rather than a narrow ultra-rare niche.
  2. A crowded "emerge with cash" cycle. October 2026 has seen a wave of large biotech launches: Matchpoint Therapeutics ($150M Series B), OMass Therapeutics ($310M Series C), and Solstice Oncology ($225M Series A) all priced in the same window. Estuary's $103 million puts it in the upper-middle tier of this cohort — enough for multiple clinical programs but far leaner than the platform plays.

What founders and investors should watch

For founders: ADPKD illustrates how a disease can be both common and commercially underserved. The biggest unmet-need opportunities are not always rare diseases with headline prices; they can be prevalent chronic conditions where existing drugs underperform. Patient-linked capital (foundation funds, disease-adjacent family offices) can de-risk early rounds and bring credibility that pure financial investors cannot.

For investors: the kidney gene-therapy space is effectively a greenfield. The first company to show durable clinical benefit will set the commercial bar and attract pharma partnership interest — and the technical risk is correspondingly high. Estuary's trial readouts will be watched closely by every large-cap pharma with a renal pipeline.

Angeled.com connects founders building in this space with investors.

Read Next